News and Press

Boston, MA SEPTEMBER 19, 2023 – Sean Doherty has been honored as a PharmaVoice 100 winner. This annual list recognizes the most inspiring people in the life sciences industry.

PharmaVoice100 honorees are selected from a pool of nominations submitted by readers and colleagues, and then evaluated by the PharmaVoice team. This year’s honorees include: Standout execs, Trailblazers, Cancer care visionaries, Clinical trial gurus, Patient heroes, Entrepreneurs, Tech wizards, Rare disease warriors, and Brand and commercialization pros.

“This industry is a ground-breaking one capable of changing the world through science and technology. These honorees inspire advancements by guiding their teams, supporting their patients, and propelling their organizations’ missions forward. We are excited to recognize their contributions through this annual list,” said Meagan Parrish, lead editor of PharmaVoice.

Since 2005, the PharmaVoice 100 — and Red Jacket honorees — have become one of the publication’s most anticipated features. PharmaVoice developed the only awards program in the industry to recognize individuals of all ages and sectors of the life sciences — from academia to nonprofits, Big Pharma, startups, tech companies, service providers and more. The PharmaVoice 100 contains a diverse mix of professionals across a range of disciplines — from the clinic to the C-suite — who are making meaningful contributions in their fields and striving to improve outcomes for patients.

This year, we will also celebrate our 2023 PharmaVoice 100 honorees during a virtual two-day event PharmaVoice is hosting with its sister publication BioPharmaDive called “The Next Frontier of the Life Sciences” on Oct. 25-26. Hosted by award-winning journalists, this event will feature a range of keynotes, panel discussions and fireside chats on the critical trends facing the industry including innovation, genetic medicine, research hot spots, the biotech market, clinical trial tech advancements and more.

The event will wrap up on Thursday Oct. 26 at 3:40p with a PharmaVoice 100 celebration where we will salute this year’s honorees and announce the 2023 Red Jacket (the PharmaVoice 100 “hall of fame”) recipients.

—

About the JDRF T1D Fund

Our aim is to create a new investment market aimed at delivering solutions to those living with or at risk of developing T1D. Launched in December 2016, the T1D Fund is a combination of venture capital and philanthropy focused solely on T1D. It’s the first scale, mission-driven venture philanthropy fund focused on equity investments in companies developing life-changing T1D products. The portfolio consists of therapeutics, devices, vaccines, and diagnostics. We already have made several investments and the list will only continue to grow.

About PharmaVoice
PharmaVoice is a leading industry publication operated by Industry Dive. Our stories deliver the most important voices and ideas in the life sciences to industry leaders.

About Industry Dive
Industry Dive, an Informa business, is a leading business journalism company. Over 14 million decision-makers across 20+ competitive industries rely on our exclusive insight and analysis delivered through more than 30 publications.